Total Payments
$2.0M
2024 Payments
$295,159
Companies
56
Transactions
2,115
Medicare Patients
16,420
Medicare Billing
$13.7M
Payment Breakdown by Category
Other$859,659 (43.7%)
Consulting$837,319 (42.6%)
Travel$160,426 (8.2%)
Food & Beverage$55,370 (2.8%)
Research$51,934 (2.6%)
Education$810.82 (0.0%)
Gifts$19.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $837,319 | 382 | 42.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $801,247 | 189 | 40.8% |
| Travel and Lodging | $160,426 | 508 | 8.2% |
| Food and Beverage | $55,370 | 963 | 2.8% |
| Unspecified | $51,934 | 37 | 2.6% |
| Honoraria | $27,381 | 15 | 1.4% |
| Current or prospective ownership or investment interest | $20,013 | 4 | 1.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $7,400 | 2 | 0.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,413 | 2 | 0.1% |
| Acquisitions | $1,150 | 1 | 0.1% |
| Entertainment | $1,056 | 2 | 0.1% |
| Education | $810.82 | 9 | 0.0% |
| Gift | $19.40 | 1 | 0.0% |
Payments by Type
General
$1.9M
2,078 transactions
Research
$51,934
24 transactions
Ownership
$0
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $458,189 | 436 | $0 (2024) |
| Allergan, Inc. | $325,819 | 472 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $174,198 | 118 | $0 (2023) |
| Apellis Pharmaceuticals, Inc. | $154,042 | 153 | $0 (2024) |
| F. Hoffmann-La Roche AG | $123,662 | 53 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $121,390 | 202 | $0 (2024) |
| Genentech, Inc. | $101,412 | 97 | $0 (2024) |
| EyePoint Pharmaceuticals US, Inc. | $71,542 | 69 | $0 (2024) |
| ABBVIE INC. | $71,468 | 58 | $0 (2024) |
| Astellas Pharma US Inc | $66,371 | 39 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $295,159 | 304 | Regeneron Healthcare Solutions, Inc. ($55,848) |
| 2023 | $213,836 | 221 | Apellis Pharmaceuticals, Inc. ($49,461) |
| 2022 | $272,409 | 263 | Genentech USA, Inc. ($77,466) |
| 2021 | $211,236 | 221 | Genentech USA, Inc. ($60,794) |
| 2020 | $163,184 | 144 | Allergan, Inc. ($45,317) |
| 2019 | $332,826 | 328 | Novartis Pharmaceuticals Corporation ($107,425) |
| 2018 | $255,131 | 337 | Allergan Inc. ($89,637) |
| 2017 | $221,756 | 297 | Genentech USA, Inc. ($89,591) |
All Payment Transactions
2,115 individual payment records from CMS Open Payments — Page 1 of 85
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 12/18/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $119.72 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/18/2024 | Glaukos Corporation | iDose (Device) | Food and Beverage | Cash or cash equivalent | $99.66 | General |
| Category: Glaucoma | ||||||
| 12/17/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $25.82 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/15/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $1.68 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/14/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $44.71 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/13/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $8,000.00 | General |
| 12/13/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $1,105.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/13/2024 | ABBVIE INC. | OZURDEX (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: EYE CARE | ||||||
| 12/13/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Consulting Fee | Cash or cash equivalent | $473.00 | General |
| Category: Ophthalmology | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $103.91 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/13/2024 | ABBVIE INC. | OZURDEX (Drug) | Travel and Lodging | In-kind items and services | $96.52 | General |
| Category: EYE CARE | ||||||
| 12/13/2024 | ABBVIE INC. | OZURDEX (Drug) | Travel and Lodging | In-kind items and services | $25.46 | General |
| Category: EYE CARE | ||||||
| 12/13/2024 | ABBVIE INC. | OZURDEX (Drug) | Travel and Lodging | In-kind items and services | $16.00 | General |
| Category: EYE CARE | ||||||
| 12/13/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $15.72 | General |
| Category: EYE CARE | ||||||
| 12/12/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,720.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/12/2024 | Genentech, Inc. | Vabysmo (Drug) | Consulting Fee | Cash or cash equivalent | $975.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $27.49 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $1.75 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/11/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $133.87 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,780.97 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/10/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 12/10/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 12/10/2024 | Sandoz Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $32.76 | General |
| Category: Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PALADIN | Alimera Sciences, Inc. | $10,550 | 3 |
| A PHASE II MULTICENTER, RANDOMIZED, ACTIVE TREATMENT-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF THE RANIBIZUMAB PORT DELIVERY SYSTEM FOR SUSTAINED DELIVERY OF RANIBIZUMAB IN PATIENTS WITH SUBFOVEAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | F. Hoffmann-La Roche AG | $9,240 | 4 |
| A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration | Regeneron Pharmaceuticals, Inc. | $5,188 | 3 |
| PDS Endophthalmitis Case Series | F. Hoffmann-La Roche AG | $4,645 | 1 |
| PDS PHASE 3 ARCHWAY | F. Hoffmann-La Roche AG | $4,557 | 2 |
| Port Delivery System of Ranibizumab Extension Study | F. Hoffmann-La Roche AG | $4,288 | 3 |
| KEY SURGICAL PEARLS OF THE IMPLANT INSERTION PROCEDURE FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB PDS | F. Hoffmann-La Roche AG | $3,577 | 1 |
| KEY SURGICAL PEARLS OF THE PDS IMPLANT INSERTION PROCEDURE | F. Hoffmann-La Roche AG | $2,602 | 1 |
| CR39521 STAIRWAY | F. Hoffmann-La Roche AG | $2,573 | 1 |
| EYLEA CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $2,170 | 1 |
| Faricimab Reduces Macular Leakage vs Aflibercept in Patients With DME | F. Hoffmann-La Roche AG | $1,926 | 3 |
| STAIRWAY SIMULTANEOUS BLOCKADE OF ANGIOPOIETIN-2 AND VEGF-A WITH THE BISPECIFIC ANTIBODY RO6867461 RG7716 FOR EXTENDED DURABILITY IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | F. Hoffmann-La Roche AG | $619.29 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 3,685 | 47,756 | $11.2M | $3.2M |
| 2022 | 18 | 3,932 | 20,083 | $10.8M | $3.2M |
| 2021 | 22 | 4,168 | 14,031 | $11.3M | $3.5M |
| 2020 | 21 | 4,635 | 16,486 | $12.8M | $3.9M |
Total Patients
16,420
Total Services
98,356
Medicare Billing
$13.7M
Procedure Codes
81
All Medicare Procedures & Services
81 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 178 | 1,660 | $3.3M | $1.1M | 34.5% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 130 | 37,080 | $3.7M | $1.1M | 29.0% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 68 | 1,553 | $1.5M | $281,633 | 18.4% |
| 67028 | Injection of drug into eye | Office | 2023 | 396 | 1,650 | $1.1M | $155,705 | 14.7% |
| J3490 | Unclassified drugs | Office | 2023 | 25 | 57 | $342,000 | $103,383 | 30.2% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 24 | 810 | $313,200 | $94,822 | 30.3% |
| J3590 | Unclassified biologics | Office | 2023 | 22 | 46 | $276,000 | $85,916 | 31.1% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 658 | 949 | $189,996 | $82,907 | 43.6% |
| 92134 | Imaging of retina | Office | 2023 | 809 | 1,940 | $126,160 | $54,867 | 43.5% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 16 | 294 | $126,420 | $46,507 | 36.8% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 267 | 382 | $57,352 | $24,737 | 43.1% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 183 | 183 | $40,335 | $18,211 | 45.1% |
| 92250 | Photography of the retina | Office | 2023 | 420 | 476 | $47,548 | $12,546 | 26.4% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 35 | 105 | $52,500 | $6,629 | 12.6% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 44 | 46 | $9,200 | $4,866 | 52.9% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 287 | 373 | $14,920 | $4,176 | 28.0% |
| 92242 | Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye | Office | 2023 | 14 | 14 | $7,000 | $2,794 | 39.9% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 70 | 89 | $4,450 | $1,548 | 34.8% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 19 | 21 | $3,150 | $784.05 | 24.9% |
| 92020 | Exam of the internal drainage system of eye | Office | 2023 | 20 | 28 | $1,960 | $521.04 | 26.6% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 221 | 2,150 | $4.3M | $1.5M | 35.8% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 106 | 2,680 | $2.7M | $601,681 | 22.5% |
| J3490 | Unclassified drugs | Office | 2022 | 55 | 180 | $1.1M | $320,363 | 29.7% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 66 | 8,160 | $816,000 | $243,505 | 29.8% |
| 67028 | Injection of drug into eye | Office | 2022 | 397 | 1,667 | $1.1M | $161,503 | 15.2% |
About Dr. David Eichenbaum, M.D
Dr. David Eichenbaum, M.D is a Retina Specialist healthcare provider based in St Petersburg, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144251356.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Eichenbaum, M.D has received a total of $2.0M in payments from pharmaceutical and medical device companies, with $295,159 received in 2024. These payments were reported across 2,115 transactions from 56 companies. The most common payment nature is "Consulting Fee" ($837,319).
As a Medicare-enrolled provider, Eichenbaum has provided services to 16,420 Medicare beneficiaries, totaling 98,356 services with total Medicare billing of $13.7M. Data is available for 4 years (2020–2023), covering 81 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Other Specialties Ophthalmology
- Location St Petersburg, FL
- Active Since 07/05/2006
- Last Updated 09/02/2022
- Taxonomy Code 207WX0107X
- Entity Type Individual
- NPI Number 1144251356
Products in Payments
- Lucentis (Biological) $318,099
- OZURDEX (Drug) $314,344
- BEOVU (Drug) $130,404
- VABYSMO (Drug) $85,906
- EYLEA HD (Biological) $77,631
- Vabysmo (Drug) $73,140
- Syfovre (Drug) $68,628
- EYLEA (Biological) $57,669
- Non-Covered Product (Drug) $56,341
- Izervay (Drug) $54,988
- YUTIQ (Drug) $46,668
- EVA Ophthalmic Surgical System (Device) $23,247
- ILUVIEN (Drug) $19,686
- VISUDYNE (Drug) $19,247
- ForeseeHome (Device) $18,502
- EYLEA AFLIBERCEPT INJECTION (Biological) $18,301
- EYP-1901 (Drug) $17,788
- XIPERE (Drug) $10,980
- SUSVIMO (Drug) $10,191
- ILUVIEN (Biological) $9,550
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.